Randomised trials of graft versus host disease prophylaxis in haemopoietic stem cell transplantation

Reviews on Recent Clinical Trials

Volumn 3, Issue 2, 2008, Pages 130-138

  Potter, Victoria ^a   Moore, John ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Cyclosporin methotrexate; Graft versus host disease; Graft versus leukaemia; Hemopoietic stem cell transplantation; Immunotherapy; Prophylaxis

Indexed keywords

ALEMTUZUMAB; CD4 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; HLA ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 11; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PALIFERMIN; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN RECOGNITION; AREA UNDER THE CURVE; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE FREE SURVIVAL; DONOR; DONOR SELECTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; GOLD STANDARD; GRAFT RECIPIENT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTESTINE FLORA; KIDNEY DYSFUNCTION; LEUKEMIA; MEDICAL DECISION MAKING; MESENCHYMAL STEM CELL; MONOTHERAPY; MORBIDITY; MORTALITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PATIENT MONITORING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PUVA; RANDOMIZED CONTROLLED TRIAL; REDUCED INTENSITY CONDITIONING; REGULATORY T LYMPHOCYTE; REVIEW; T CELL DEPLETION; THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VEIN OCCLUSION; WHOLE BODY RADIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; RISK FACTOR;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 46749142583     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488708784223790     Document Type: Review

References (87)

1. Pasquini M. Centre for International Blood and Marrow Transplant Research (CIBMTR). Summary Slides Part I. CIBMTR Newsletter. May 2006.
2. Pasquini M, He V, Perez W. Centre for International Blood and Marrow Transplant Research (CIBMTR). Summary Slides Part II. CIBMTR Newsletter. December 2006.
3. Lee S. New Approaches for preventing and treating chronic graft versus host disease. Blood 2005; 105: 4200-6.
4. Baird K, Pavletic S. Chronic graft versus host disease. Curr Opin Haematol 2006; 13: 426-35.
5. Cutler C, Antin JH. Chronic graft-versus-host disease. Curr Opin Oncol 2006; 18(2): 126-31.
6. Watson M, Buck G, Wheatley K, et al. UK Medical Research Council AML 10 trial. Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial. Eur J Cancer 2004; 40(7): 971-8.
7. Nash R. Haemopoietic stem cell transplantation. In: Wintrobes Clinical Haematology. Philadelphia, Lippincott, Williams and Wilkins 2004; 883-909.
8. Ozawa S, Nakaseko C, Nishimura M, et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol 2007; 137(2): 142-51.
9. Wojnar J, Giebel S, Holowiecka-Goral A, et al. The incidence and risk factors for chronic graft-versus-host-disease. Ann Transplant 2006; 11(2): 14-20.
10. Nivison-Smith I, Bradstock KF, Dodds AJ, et al. Haemopoietic stem cell transplants in Anstralia and New Zealand, 1992-2001: a progress report from the Australian Bone Marrow Transplant Recipient Registry. Intern Med J 2005; 35: 18-27.
11. Socie G, Stone JV, Wingard JR, et al. Long term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14-21.
12. Culther C, Giri S, Jeyapalan, S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral blood stem-cell and bone marrow transplantation: A meta-analysis. J Clin Oncol 2001; 19: 3685-91
13. Mohty M, Kuentz M, Michallet M, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002; 100(9): 3128-34.
14. Stem Cell Trialists' Collaborative Group: Allogeneic peripheral blood stem cell compared with bone marrow transplantation in the management of haematologic malignancies: an individual patient data meta-analysis of nine randomised trials, J Clin Oncol 2005; 23: 5074-87.
15. Brustein C, Setubal D, Wagner J. Expanding the role of umbilical cord blood transplantation. Br J Haematol 2007; 137(1): 20-35.
16. Ferrara JL. Cooke KR. Pan L. Krenger W. The immunopathophysiology of acute graft-versus-host-disease. Stem Cells 1996; 14(5): 473-89.
17. Morris E, Hill G. Advances in the understanding of acute graft-versus-host disease. Br J Haematol 2007; 137: 3-19
18. Mielcarek M. Martin PJ. Leisenring W. Flowers ME. Maloney DG. Sandmaier BM. Maris MB. Storb R. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102(2): 756-62.
19. Flomenberg N, Baxter-Lowe, L, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104(7): 1923-30.
20. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99(11): 4200-6.
21. Prentice H, Janossy G, Price-Jones L, et al. Depletion of T-lymphocytes in donor marrow prevents significant graft versus host disease in matched allogeneic leukemic marrow transplant recipients. Lancet 1984; 1: 472-5.
22. Pavletic S, Carter S, Kernan N, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomised trial in unrelated marrow donor transplantation. Blood 2005; 106(9): 3308-13.
23. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98(10): 2942-7.
24. Champlin R, Paswegg J, Zhaang M, et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities Blood 2000; 95(12): 3996-4003.
25. Wagner J, Thompson, J, Carter S, Kernan N. Unrelated Donor Marrow Transplantation Trial. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial Lancet 2005; 366(9487): 733-41.
26. Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12(5): 560-5.
27. Barge RM, Starrenburg CW, Falkenburg JH, Fibbe WE, Marijt EW, Willemze R. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience. Bone Marrow Transplant 2006; 37 (12): 1129.
28. Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 2006; 107: 1724-30.
29. Morris M, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865-71.
30. Beelen DW. Elmaagacli A. Muller KD. Hirche H. Schaefer UW. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93(10): 3267-75.
31. Storb R. Epstein RB. Graham TC. Thomas ED. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970; 9(3): 240-6.
32. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-35.
33. Storb R, Deeg H, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729-34.
34. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423-8.
35. Bacigalupo A, Lamparelli T, Gualandi F, et al. Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study. Blood 2001; 98: 3174-5.
36. Locatelli F, Bruno B, Zecca M, et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690-7.
37. Kansu E, Gooley T, Flowers ME, et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood 2001; 98(13): 3868-70.
38. Burroughs L. Mielcarek M. Leisenring W, et al. Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Transplantation. 2006; 81(6): 818-25.
39. Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000; 96(7): 2391-8.
40. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329(17): 1225-30.
41. Storb R, Pepe M, Anasetti C, et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76: 1037-1045.
42. Chao NJ. Snyder DS. Jain M, et al. Equivalence of 2 effective graft-veruzs-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant 2000; 6(3):254-61.
43. Ruutu T, Niederwieser D, Gratwohl A, et al. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 759-64.
44. Hendriks MP. Blijlevens NM. Schattenberg AV. Burger DM. Donnelly JP. Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006; 38(7):521-5.
45. Duncan N, Craddock C. Optimizing the use of cyclosporine in allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 169-74.
46. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92(7): 2303-14.
47. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96(6): 2062-8.
48. Hiraoka A. Ohashi Y. Okamoto S, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28(2): 181-5.
49. Antin J, Kim H, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-veruts-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003, 102: 1601-5.
50. Cutler C, Kim HT, Hochberg E, et al. Sonis S. Soiffer RJ. Antin JH. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004; 10(5): 328-36.
51. Cutler C, Li S, Ho V, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation Blood 2007; 109: 3108-14.
52. Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34(7): 621-5.
53. Nieto Y, Patton N, Hawkins T, et al. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biol Blood Marrow Transplant 2006; 12(2): 217-25.
54. Nash RA, Johnston L, Parker P, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11(7): 495-505.
55. Neumann F, Graef T, Tapprich C, et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005; 35(11): 1089-93.
56. Rodriguez R, Parker P, Nademanee A, et al. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplant 2004; 33(11):1123-9.
57. Osunkwo I, Bessmertny O, Harrison L, et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2004; 10(4): 246-58.
58. Ruutu T, Eriksson B, Remes K, et al. Nordic Bone Marrow Transplantation Group. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100(6): 1977-83.
59. Blazar BR, Weisdorf DJ, Defor T, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108(9): 3216-22.
60. Chao NJ, Parker PM, Niland JC, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant 1996; 2(2): 86-92.
61. Antin JH, Weisdorf D, Neuberg D, et al. Interleukin-1 blockade does not prevent acute graft-versus-host disase: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2001; 100(10): 3479-82.
62. Antin JH, Lee SJ, Neuberg D, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29(5): 373-7.
63. Cordonnier C, Chevret S, Legrand M, et al. GREFIG Study Group. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 2003; 139(1): 8-18.
64. Mielke S. Solomon SR. Barrett AJ. Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy 2005; (2): 109-15.
65. Solomon SR, Mielke S, Savani BN, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005; 106(3): 1123-9.
66. Kalaycio M, Rybicki L, Pohlman B, et al. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. Bone Marrow Transplant 2005; 35(3): 247-52.
67. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196(3): 389-99.
68. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9(9): 1144-50.
69. Mutis T, van Rijn RS, Simonetti ER, et al. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice. Clin Cancer Res 2006; 12(18): 5520-5.
70. + regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005; 106: 2903-11.
71. Rezvani K. Mielke S. Ahmadzadeh M. Kilical Y. Savani BN. Zeilah J. Keyvanfar K. Montero A. Hensel N. Kurlander R. Barrett AJ. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108(4): 1291-7.
72. Schneider M, Munder M, Karakhanova S, et al. The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation. Clin Lab Haematol 2006; 28(6): 382-90.
73. Vela-Ojeda J, Garcia-Ruiz Esparza MA, Reyes-Maldonada E, et al. Clinical relevance of NK, NKT, and dendritic cell dose in patient receiving G-CSF mobilized periheral blood allogeneic stem cell transplantation. Ann Hematol 2006; 85(2): 113-20.
74. Meignin V, Peffault de Latour R, Zuber J, et al. Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. Exp Hematol 2005; 33(8): 894-900.
75. + regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390-9.
76. Porter SB. Liu B. Rogosheske J. Levine BL. June CH. Kohl VK. Wagner JE. Miller JS. Blazar BR. Suppressor function of umbilical cord blood-derived CD4+CD25+ T-regulatory cells exposed to graft-versus-host disease drugs. Transplantation 2006; 82(1): 23-9.
77. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363(9419): 1439-41.
78. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease Transplantation 2006; 81(10): 1390-7.
79. Aggarwal S, Pittenger M. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-22.
80. Zikos P, Van Lint MT, Frassoni F, et al. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate. Blood 1998; 91(9): 3503-8.
81. Platzbecker U, Pabst C, Kiani A, et al. Graft Versus Host Disease Prophylaxis with Everolimus and Tacrolimus in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukaemia (AML) Receiving Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT). Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 2886.
82. Gorgun G, Miller KB, Foss M. Immunologic mechanisms of extracorporeal photochemotherapy in chornic graft-versus-host-disease. Blood 2002; 100 (3): 941-7.
83. Krishna V, Couriel D, Champlin R. Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis. Biol Blood Marrow Transplant 2006; 12: 1-6.
84. Couriel D, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006; 107: 3074-80.
85. Grenix H, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92(9): 3098-104.
86. Abbyankhar S, Shaughnessy P, Bolwell B, et al. A multi-institutional study of extracorporeal photoimmune therapy with Uvadex for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic haemopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11(2): 37.
87. Atkinson K, Biggs J, Dodds A, et al. High incidence of early leukaemic relapse in patients given T cell depleted HLA-identical sibling marrow transplants for acute leukaemia in first remission. Aust NZ J Med 1988; 18: 587-93.